Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer

Abstract Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase T cell infiltration into the tumor, and oral cyclophospha...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Spencer R. Rosario, Mark D. Long, Shanmuga Chilakapati, Eduardo Cortes Gomez, Sebastiano Battaglia, Prashant K. Singh, Jianmin Wang, Katy Wang, Kristopher Attwood, Suzanne M. Hess, AJ Robert McGray, Kunle Odunsi, Brahm H. Segal, Gyorgy Paragh, Song Liu, Jennifer A. Wargo, Emese Zsiros
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Nature Portfolio 2024-12-01
Serie:	Nature Communications
Länkar:	https://doi.org/10.1038/s41467-024-54565-8
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!